Trial Profile
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Atherosclerosis
- Focus Pharmacodynamics
- 12 Feb 2013 Additional lead trial centre and trial company Novartis added as reported by ClinicalTrials.gov.
- 20 Jan 2012 Planned end date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.